Includes technologies from the cell and gene therapy space, including NK cells, stem cells, T cells, AAV, Adenovirus, CRISPR, DNA, Lentivirus, RNA and vaccinia.
University of Pittsburgh researchers have developed a novel set of quality control standards for selecting human corneal stromal stem cells (CSSCs) with optimal regenerative capabilities.
Age-related macular degeneration (AMD) is the world’s leading cause of blindness among the elderly. A projected 288 million people worldwide will live with AMD by the year 2040, and the cost of treatment already exceeds $350 billion.
Glaucoma is the second leading cause of irreversible blindness worldwide. The major risk factor for most glaucoma patients — and the focus of treatment — is increased intraocular pressure (IOP).
